All Blogs

Aug 13, 2018

Personalized Medicine (also referred as Precision Medicine) is a tailored approach of deciding and predicting treatment practices based on the molecular analysis of patient’s proteins, metabolites and genetic makeup. This specific treatment approach can be considered as an extension of traditional approaches to unde...

Aug 10, 2018

Sarepta builds in gene therapy with $30M Lacerta deal Sarepta has dampen its enthusiasm for an ongoing gene therapy candidate. Sarepta has made a tie-up with lacerta that will add 3 more programs to 8 already existing and are ready to expand its focus beyond muscular dystrophy. Sarepta has committed to pay Lacerta ...

Aug 09, 2018

 Can CRISPR really fix genetic mutation in human embryos?  Team of scientists who created controversial blockbuster last year claim that they have fixed a disease-causing mutation in human embryos using gene editing technique CRISPR. Team has released fresh evidence supporting their work. Critics argued that the ev...

Aug 08, 2018

Teva’s migraine drug is expected to launch this year despite the delay in FDA approval Teva Pharmaceutical’s fremanezumab for treating migraine is expected to launch later this year.  Celltrion disclosed that U.S. drug regulators issued a Form 483 for its plant in Incheon, South Korea on tuesdsy. Eight manufacturin...

Aug 07, 2018

Progenics got FDA Approval on Iobenguane I 131 for Rare Adrenal Gland Tumors  A good news for unresectable rare adrenal tumor  patients as oncologists now have a new treatment to offer . On July 30, 2018, the Food and Drug Administration approved Progenics Pharmaceuticals iobenguane I for adult and pediatric patient...

Aug 06, 2018

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) – a lesser developed window Mucopolysaccharidosis (MPS) is a group of rare, hereditary and incurable “storage diseases”, which is named after mucopolysaccharides (sugars bound to proteins). The stored mucopolysaccharides are called as glycosaminoglycans (GAGs). ...

Aug 02, 2018

Sutro Biopharma nets $85.4M to drive antibody-drug conjugates Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which includes a pair of antibody-drug conjugates (ADCs).Of its ADC assets, STRO-001 is in phase 1 for lymphoma and multiple my...

Aug 01, 2018

‘Reprogrammed’ stem cells to be tested in people with Parkinson’s Doctors in Japan are poised to implant neural cells made from ‘reprogrammed’ stem cells into the brains of people with Parkinson’s disease. It is only the third clinical application of induced pluripotent stem (iPS) cells, which are developed by repro...

Jul 27, 2018

Niemann-Pick disease type C (NPC) is a lipid storage disease that can present in infants, children, or adults. Neonates can present with ascites and severe liver disease from infiltration of the liver and/or respiratory failure from infiltration of the lungs. The classic presentation occurs in mid-to-late childhood ...

Jul 25, 2018

The FDA has approved AbbVie's Gonadotropin-Releasing Hormone (GnRH) antagonist Elagolix on Tuesday. FDA has given green light to the first oral treatment for endometriosis pain. The drug is branded as Orilissa, and is expected to be available in U.S. pharmacies in August. It will carry a list price of about $850 per...